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Molly: The Not So Convincing Truth of MDMA 
Alison Cromer 
 
 Molly. XTC. E. Adam.  Or simply MDMA. No matter what the name, 3,4-
methylenedioxy-methamphetamine has made its way into the mainstream media over 
the last 20 years, taking over the club and nightlife scene in a wave of warm fuzzy 
thoughts. Following in its footsteps, the rumors of depression, brain damage, and death 
have lurked in the shadows, scaring off anyone who has a ‘decent’ amount of common 
sense. However, these rumors are just that- rumors. The truth is, the long held stigmas 
about MDMA have little support through scientific evidence and the opposite may in fact 
be true- MDMA should not be a schedule 1 drug for it fails to show brain damage that 
cannot be protected again or prevented, addictive properties, and shows promising 
therapeutic application in psychotherapy.  
The facts are this: MDMA was born out of the German pharmaceutical company 
Merck and Co., whose primary goal was to synthesize different pharmaceutical 
compounds (6). In the 1970’s, MDMA made its way to the United States and took up 
residence in psychotherapy practices across the nation (6). It wasn’t until the turn of the 
century that the Food and Drug Administration began minor tests on the compound to 
start the process for approval for medical use. The hope was that MDMA would be able 
to combat a host of psychotherapeutic issue including anxiety and PTSD. Earning itself 
the name “penicillin for the soul,” MDMA was on the fast track to fame and fortune (6). 
In the late 1980’s, MDMA took a side trip to the streets. The testing by the FDA had 
proven inconclusive and Drug Enforcement Agency (DEA) labeled the compound as a 
Schedule 1 Drug: a substance that has high abuse potential and no medical benefits 
(4).  
 The effects of the drug are labeled as a psychoactive stimulant similar to 
amphetamines and on occasion a hallucinogen similar to LSD (1). On a chemical level, 
MDMA causes primarily serotonin, but also dopamine and norepinephrine, to rush out of 
the brain cells, giving a feeling of euphoria (3). Users of MDMA have reported increased 
feeling of well being, emotional openness, and energy while under the influence (1). The 
experience of being on MDMA has earned the nickname “rolling” for the wave of high 
that a user feels (7). Yet, for the amazing high, users also feel an extreme low marked 
by depression, anxiety, sleep abnormality and minor confusion (3). The low can be felt 
for several days after dosing, a time period in which the brain recovers from the high 
and reestablished proper levels of serotonin and other neurotransmitters. 
 One of the most terrifying and most discussed about topics surrounding the use 
of MDMA is the effect users suffer after prolonged use.  Chronic abuse has shown 
neurotoxicity that had lead to the depletion of serotonin structures in the brain, creating 
“holes” in the gray matter (2). Chronic depression, memory loss, addiction and even 
death are supposed marked traits of MDMA abusers (3). The after math of MDMA has 
been noted to take up to seven years to see substantial regrowth in damaged areas of 
the brain (2). These traits are what MDMA is known for: the extreme high and the even 
more extreme low. Ever since it’s creation, this bad reputation has plagued MDMA. 
 However, when looking even more closely at the studies, imperfections began to 
shine through. As for the addiction that is implied through the labeling of MDMA as a 
schedule 1 drug, there is little support to prove that MDMA is an addictive substance. It 
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is argued that the side effects, including blurred vision, sweating and muscle tightness, 
are actually deterrents of physical addiction (4). Psychological addiction is more of a 
gray area, however. The modern belief of psychopharmacology is that psychological 
addiction lies within the user rather than the substance (4). Thus taking away one 
criteria needed to place MDMA as a schedule 1 drug. 
 Furthermore, MDMA has been used successfully in several psychotherapeutic 
applications. Patients are prescribed MDMA are taken daily in order to tackle specific 
issues which are later addressed in therapy. The emotional openness, confidence, 
sense of self, and willingness to forgive that is felt while on MDMA has improved 
patients who have battled with low self esteem, poor communication skills, and anxiety 
disorders (4). No other substance has lead patients to break away from their issues and 
look at themselves with a rational frame of mind (4). Paired with the lack of addictive 
nature, the therapeutic effects of MDMA completely exclude the substance from being a 
schedule 1 drug. 
 Aside from the improper labeling of MDMA, studies focusing on the long-term 
effects of MDMA have been misconstrued to fit the bill.  Studies supported by the 
National Institute of Health showed great support for neural damage and the notion that 
even after years of abstinence, neural plasticity will have done little in the ways of 
repairing the damage done by MDMA (2). The catch, however, is that some of the most 
convincing work on neural plasticity were done on monkey test subjects opposed to 
humans (2). In human subjects, use of MDMA alone has failed to show significant 
damage done to the brain when used in moderation (3). If damage is done, it is most 
likely due to use of MDMA in coalition with other substances such as ketamine, cocaine, 
and other amphetamines (3). 
 In the last few years, users of MDMA have also taken up the habit of  “pre-
loading” and “post-loading” before and after the ingestion of MDMA (5). Since MDMA 
works on a cellular level in the brain, pre and post loading are used to control the affects 
of MDMA through the use of vitamins and supplements. One popular preloading 
supplement is 5-HTP, which directly influences the production of serotonin (5). 5-HTP is 
taken anywhere between a day to a few hours before dosing on MDMA to create high 
levels of serotonin which will create a more powerful high when the serotonin is 
released (5). Magnesium can also be taken to prevent the clenching of the jaw 
commonly associated with MDMA use (5). Post-loading practices may include taking 
additional 5-HTP and SSRI’s in order to reestablish the reservoirs of serotonin in the 
brain cells as well as prevent reuptake of serotonin, which effectively lowers serotonin 
production (5). Though studies on these techniques are still in their infant stages, users 
who pre/post load testify the impact such practices make on the come down and after 
affects of MDMA use. 
 All in all, MDMA has retained a bad reputation for far too long with little evidence 
to support it. Though damage and addiction are possible, only in extreme cases can 
they be seen. Even minor, more immediate effects of MDMA have the potential to be 
combatted. Also, MDMA offers a promising impact in the field of psychotherapy. With 
the current increase of cases of PTSD and anxiety disorders, a powerful substance like 
MDMA could greatly improve the quality of life for many people. If nothing else, MDMA 
needs to be reevaluated through unbiased eyes and recognized for its true power.  
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